TY - JOUR AU - Molnár, Tihamér AU - Lehoczki, Andrea Marianna AU - Fekete, Mónika AU - Várnai, Réka AU - Zavori, Laszlo AU - Erdő-Bonyár, Szabina AU - Simon, Diána AU - Berki, Tímea AU - Csécsei, Péter AU - Ezer, Erzsébet TI - Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches JF - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) J2 - GEROSCIENCE VL - In press PY - 2024 SN - 2509-2715 DO - 10.1007/s11357-024-01165-5 UR - https://m2.mtmt.hu/api/publication/34824081 ID - 34824081 N1 - * Megosztott szerzőség AB - The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has introduced the medical community to the phenomenon of long COVID, a condition characterized by persistent symptoms following the resolution of the acute phase of infection. Among the myriad of symptoms reported by long COVID sufferers, chronic fatigue, cognitive disturbances, and exercise intolerance are predominant, suggesting systemic alterations beyond the initial viral pathology. Emerging evidence has pointed to mitochondrial dysfunction as a potential underpinning mechanism contributing to the persistence and diversity of long COVID symptoms. This review aims to synthesize current findings related to mitochondrial dysfunction in long COVID, exploring its implications for cellular energy deficits, oxidative stress, immune dysregulation, metabolic disturbances, and endothelial dysfunction. Through a comprehensive analysis of the literature, we highlight the significance of mitochondrial health in the pathophysiology of long COVID, drawing parallels with similar clinical syndromes linked to post-infectious states in other diseases where mitochondrial impairment has been implicated. We discuss potential therapeutic strategies targeting mitochondrial function, including pharmacological interventions, lifestyle modifications, exercise, and dietary approaches, and emphasize the need for further research and collaborative efforts to advance our understanding and management of long COVID. This review underscores the critical role of mitochondrial dysfunction in long COVID and calls for a multidisciplinary approach to address the gaps in our knowledge and treatment options for those affected by this condition. LA - English DB - MTMT ER - TY - JOUR AU - Závori, László AU - Várnai, Réka AU - Molnár, Tihamér AU - Szirmay, Balázs AU - Borbásné Farkas, Kornélia AU - Schwarcz, Attila AU - Csécsei, Péter TI - Acute Phase Protein Orosomucoid (Alpha-1-Acid Glycoprotein) Predicts Delayed Cerebral Ischemia and 3-Month Unfavorable Outcome after Aneurysmal Subarachnoid Hemorrhage JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 24 PY - 2023 IS - 20 PG - 10 SN - 1661-6596 DO - 10.3390/ijms242015267 UR - https://m2.mtmt.hu/api/publication/34202983 ID - 34202983 N1 - Export Date: 13 November 2023 Correspondence Address: Szirmay, B.; Department of Laboratory Medicine, Hungary; email: szirmay.balazs@pte.hu LA - English DB - MTMT ER - TY - JOUR AU - Csécsei, Péter AU - Oláh, Csaba Zsolt AU - Várnai, Réka AU - Simon, Diána AU - Erdő-Bonyár, Szabina AU - Berki, Tímea AU - Czabajszki, Mate AU - Závori, László AU - Schwarcz, Attila AU - Molnár, Tihamér TI - Different Kinetics of Serum ADAMTS13, GDF-15, and Neutrophil Gelatinase-Associated Lipocalin in the Early Phase of Aneurysmal Subarachnoid Hemorrhage JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 24 PY - 2023 IS - 13 PG - 16 SN - 1661-6596 DO - 10.3390/ijms241311005 UR - https://m2.mtmt.hu/api/publication/34043095 ID - 34043095 AB - Growth differentiation factor 15 (GDF-15), neutrophil gelatinase-associated lipocalin (NGAL), and ADAMTS13 have previously been implicated in the pathophysiological processes of SAH. In the present study, we aim to examine their role in the early period of SAH and their relationship to primary and secondary outcomes. Serum samples were collected at five time periods after SAH (at 24 h (D1), at 72 h (D3), at 120 h (D5), at 168 h (D7) and at 216 h (D9), post-admission) and) were measured by using MILLIPLEX Map Human Cardiovascular Disease (CVD) Magnetic Bead Panel 2. We included 150 patients with SAH and 30 healthy controls. GDF-15 levels at D1 to D9 were significantly associated with a 3-month unfavorable outcome. Based on the ROC analysis, in patients with a good clinical grade at admission (WFNS I-III), the GDF-15 value measured at time point D3 predicted a 3-month unfavorable outcome (cut-off value: 3.97 ng/mL, AUC:0.833, 95%CI: 0.728–0.938, sensitivity:73.7%, specificity:82.6%, p < 0.001). Univariate binary logistic regression analysis showed that serum NGAL levels at D1-D5 and ADAMTS13 levels at D7-D9 were associated with MVS following SAH. GDF-15 is an early indicator of a poor 3-month functional outcome even in patients with mild clinical conditions at admission. LA - English DB - MTMT ER - TY - JOUR AU - Zavori, Laszlo AU - Molnár, Tihamér AU - Várnai, Réka AU - Kanizsai, Andrea AU - Nagy, Lajos AU - Vadkerti, Bence AU - Szirmay, Balázs AU - Schwarcz, Attila AU - Csécsei, Péter TI - Cystatin-c May Indicate Subclinical Renal Involvement, While Orosomucoid Is Associated with Fatigue in Patients with Long-COVID Syndrome JF - JOURNAL OF PERSONALIZED MEDICINE J2 - J PERS MED VL - 13 PY - 2023 IS - 2 PG - 11 SN - 2075-4426 DO - 10.3390/jpm13020371 UR - https://m2.mtmt.hu/api/publication/33647476 ID - 33647476 N1 - Salisbury NHS Foundation Trust, Salisbury, SP2 8BJ, United Kingdom Department of Anaesthesiology and Intensive Care, Medical School, University of Pecs, Pecs, 7624, Hungary Department of Primary Health Care, Medical School, University of Pecs, Pecs, 7624, Hungary Department of Dentistry, Medical School, University of Pecs, Pecs, Pecs, 7624, Hungary Department of Applied Chemistry, University of Debrecen, Debrecen, 4032, Hungary Department of Laboratory Medicine, Medical School, University of Pecs, Pecs, 7624, Hungary Department of Neurosurgery, Medical School, University of Pecs, Pecs, 7624, Hungary Export Date: 13 November 2023 Correspondence Address: Szirmay, B.; Department of Laboratory Medicine, Hungary; email: szirmay.balazs@pte.hu LA - English DB - MTMT ER - TY - JOUR AU - Kanizsai, Andrea AU - Zavori, Laszlo AU - Molnár, Tihamér AU - Tőkés-Füzesi, Margit AU - Szalai, Zoltan AU - Berecz, Janos AU - Várnai, Réka AU - Péterfi, Zoltán AU - Schwarcz, Attila AU - Csécsei, Péter TI - Adverse Reactions after Booster SARS-CoV-2 Vaccination Have Less Impact on Antibody Response than after Basic Vaccination Scheme JF - VACCINES (BASEL) J2 - VACCINES-BASEL VL - 11 PY - 2023 IS - 1 PG - 10 SN - 2076-393X DO - 10.3390/vaccines11010182 UR - https://m2.mtmt.hu/api/publication/33567482 ID - 33567482 AB - Background: It is known that adverse reactions following SARS-CoV-2 vaccinations show a positive correlation with the subsequent antibody titer. However, it is not clear how the adverse reactions following the booster vaccination are related to the antibody levels that can be measured after a 3rd dose. The primary goal of this study was to investigate whether the adverse reactions following the booster vaccination show a correlation with subsequent antibody levels. Methods: Adverse reactions occurring within 7 days after the 3rd vaccination were recorded and the anti-SARS-CoV-2 spike protein immunoglobulin (Ig) level in the venous blood was measured on post-vaccination 14th, 60th and 120th days. Results: A total of 218 volunteers were included in the study. Main findings: (i) The adverse reactions that appeared after the booster dose did not show a positive correlation with the subsequent antibody level, except a correlation in the case of fever; (ii) there were more symptomatic patients in the group receiving heterologous booster vaccine, (iii) fever after the 2nd dose was independently associated with a reduction in the likelihood of COVID-19 positivity after the booster dose. Conclusion: No adverse reactions, but fever showed a correlation with the antibody level after the booster SARS-CoV-2 vaccine. LA - English DB - MTMT ER - TY - JOUR AU - Molnár, Tihamér AU - Riba, János AU - Várnai, Réka AU - Závori, László AU - Erdő-Bonyár, Szabina AU - Simon, Diána AU - Berki, Tímea AU - Csécsei, Péter TI - Long-COVID tünetek és mitokondriális diszfunkció JF - FOCUS MEDICINAE J2 - FOCUS MEDICINAE VL - 24 PY - 2022 IS - 3 SP - 18 EP - 23 PG - 6 SN - 1419-0478 UR - https://m2.mtmt.hu/api/publication/33564977 ID - 33564977 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Spántler, Dóra AU - Csécsei, Péter AU - Böröcz, Katalin AU - Berki, Tímea AU - Zavori, Laszlo AU - Schwarcz, Attila AU - Lenzsér, Gábor AU - Molnár, Tihamér TI - Serum Periostin May Help to Identify Patients with Poor Collaterals in the Hyperacute Phase of Ischemic Stroke JF - DIAGNOSTICS J2 - DIAGNOSTICS VL - 12 PY - 2022 IS - 8 PG - 11 SN - 2075-4418 DO - 10.3390/diagnostics12081942 UR - https://m2.mtmt.hu/api/publication/33050416 ID - 33050416 N1 - Department of Anaesthesiology and Intensive Care and Department of Neurosurgery, Medical School, University of Pecs, Pecs, 7624, Hungary Department of Neurosurgery, Medical School, University of Pecs, Pecs, 7624, Hungary Department of Immunology and Biotechnology, Medical School, University of Pecs, Pecs, 7624, Hungary Salisbury NHS Foundation Trust, Salisbury, SP2 8BJ, United Kingdom Export Date: 13 November 2023 Correspondence Address: Csecsei, P.; Department of Neurosurgery, Hungary; email: csecseipeti@yahoo.com AB - Background: Periostin is a glycoprotein that mediates cell functions in the extracellular matrix and appears to be a promising biomarker in neurological damage, such as ischemic stroke (IS). We aimed to measure serum periostin levels in the hyperacute phase of ischemic stroke to explore its predictive power in identification of patients with poor collaterals (ASPECT < 6). Methods: We prospectively enrolled 122 patients with acute ischemic stroke within the first 6 h after onset. The early ischemic changes were evaluated by calculating ASPECT score on admission using a native CT scan. An unfavorable outcome was defined as the modified Rankin Scale (mRS) > 2 at 90 days follow-up. Blood samples were collected on admission immediately after CT scan and periostin serum concentrations were determined by ELISA. Results: The admission concentration of serum periostin was significantly higher in patients with unfavorable outcome than in patients with favorable outcome (615 ng/L, IQR: 443–1070 vs. 390 ng/L, 260–563, p < 0.001). In a binary logistic regression model, serum periostin level was a significant predictor for ASPECT < 6 status on admission, within 6 h after stroke onset (OR, 5.911; CI, 0.990–0.999; p = 0.015). Conclusion: Admission periostin levels can help to identify patients who are not suitable for neurointervention, especially if advanced neuroimaging is not available. LA - English DB - MTMT ER - TY - JOUR AU - Spántler, Dóra AU - Molnár, Tihamér AU - Simon, Diána AU - Berki, Tímea AU - Büki, András AU - Schwarcz, Attila AU - Csécsei, Péter TI - Biomarker Associations in Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Hemorrhage JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 23 PY - 2022 IS - 15 PG - 15 SN - 1661-6596 DO - 10.3390/ijms23158789 UR - https://m2.mtmt.hu/api/publication/33041676 ID - 33041676 AB - The prognosis for patients with aneurysmal subarachnoid hemorrhage (aSAH) is heavily influenced by the development of delayed cerebral ischemia (DCI), but the adequate and effective therapy of DCI to this day has not been resolved. Multiplex serum biomarker studies may help to understand the pathophysiological processes underlying DCI. Samples were collected from patients with aSAH at two time points: (1) 24 h (Day 1) and (2) 5–7 days after ictus. Serum concentrations of eotaxin, FGF-2, FLT-3L, CX3CL1, Il-1b, IL-4, IP-10, MCP3, and MIP-1b were determined using a customized MILLIPLEX Human Cytokine/Chemokine/Growth Factor Panel A multiplex assay. The functional outcome was defined by the modified Rankin scale (favorable: 0–2, unfavorable: 3–6) measured on the 30th day after aSAH. One-hundred and twelve patients with aSAH were included in this study. The median level of CX3CL1 and MCP-3 measured on Days 5–7 were significantly higher in patients with DCI compared with those without DCI (CX3CL1: with DCI: 110.5 pg/mL, IQR: 82–201 vs. without DCI: 82.6, 58–119, p = 0.036; and MCP-3: with DCI: 22 pg/mL (0–32) vs. without DCI: 0 (0–11), p < 0.001). IP-10, MCP-3, and MIP-1b also showed significant associations with the functional outcome after aSAH. MCP-3 and CX3CL1 may play a role in the pathophysiology of DCI. LA - English DB - MTMT ER - TY - JOUR AU - Abada, Alan AU - Csécsei, Péter AU - Ezer, Erzsébet AU - Lenzsér, Gábor AU - Hegyi, Péter AU - Szolics, Alex AU - Mérei, Ákos AU - Szentesi, Andrea Ildikó AU - Molnár, Tihamér TI - General Anesthesia-Related Drop in Diastolic Blood Pressure May Impact the Long-Term Outcome in Stroke Patients Undergoing Thrombectomy JF - JOURNAL OF CLINICAL MEDICINE J2 - J CLIN MED VL - 11 PY - 2022 IS - 11 PG - 10 SN - 2077-0383 DO - 10.3390/jcm11112997 UR - https://m2.mtmt.hu/api/publication/32843086 ID - 32843086 N1 - Department of Anesthesiology and Intensive Care, Medical School, University of Pecs, Pecs, 7624, Hungary Centre for Translational Medicine, Semmelweiss University, Budapest, 1085, Hungary Department of Neurosurgery, Medical School, University of Pecs, Pecs, 7624, Hungary Department of Radiology, Örebro University Hospital, Örebro, 70281, Sweden Export Date: 13 November 2023 Correspondence Address: Csecsei, P.; Department of Neurosurgery, Hungary; email: csecsei.peter@pte.hu AB - Background: Several factors affect the efficacy of endovascular thrombectomy (EVT); however, the anesthesia-related factors have not been fully explored. We aimed to identify independent predictors of outcome by analyzing procedural factors based on a multicentric stroke registry. Methods: Data of consecutive patients with acute ischemic stroke (AIS) were extracted from the prospective STAY ALIVE stroke registry. Demographic, clinical, and periprocedural factors including hemodynamic values were analyzed in patients undergoing thrombectomy with either general anesthesia (GA) or conscious sedation (CS). Independent predictors of outcome both at 30 and 90 days based on the modified Rankin Scale (mRS: 0–2 as favorable outcome) were also explored. Results: A total of 199 patients (GA: 76 (38%) vs. CS: 117 (59%); in addition, six patients were converted from CS to GA) were included. The minimum value of systolic, diastolic, and mean arterial pressure was significantly lower in the GA compared to the CS group, and GA was associated with a longer onset to EVT time and a higher drop in all hemodynamic variables (all, p < 0.001). A higher drop in diastolic blood pressure (DBP) was even independently associated with a poor 90-day outcome (p = 0.024). Conclusion: A GA-related drop in DBP may independently predict a poor long-term outcome in stroke patients undergoing thrombectomy. LA - English DB - MTMT ER - TY - JOUR AU - Kanizsai, Andrea AU - Molnár, Tihamér AU - Várnai, Réka AU - Zavori, Laszlo AU - Tőkés-Füzesi, Margit AU - Szalai, Zoltan AU - Berecz, Janos AU - Csécsei, Péter TI - Fever after Vaccination against SARS-CoV-2 with mRNA-Based Vaccine Associated with Higher Antibody Levels during 6 Months Follow-Up JF - VACCINES (BASEL) J2 - VACCINES-BASEL VL - 10 PY - 2022 IS - 3 PG - 12 SN - 2076-393X DO - 10.3390/vaccines10030447 UR - https://m2.mtmt.hu/api/publication/32743755 ID - 32743755 AB - The effect of post-vaccination adverse events on immunogenicity is unknown. We aimed to explore relationship between post-vaccination adverse reactions and antibody levels during 6-month follow-up.Blood was serially drawn from healthcare workers after the second dose of BNT162b2 mRNA vaccine (Day 12, 30, 60, 90, 120, 150, and 180) and anti-SARS-CoV-2 spike IgG (S-IgG) levels were measured. Following each vaccine dose, volunteers completed a questionnaire regarding adverse reactions (symptomatic vs. asymptomatic groups).A total of 395 subjects received the second dose of the vaccine. The main results were as follows: (i) fever after the 2nd dose was independently associated with the median S-IgG level at all follow-up time points; (ii) significantly higher S-IgG levels were observed in the symptomatic group of patients without prior COVID-19 infection throughout the entire follow-up period; (iii) prior COVID-19 positivity resulted in higher S-IgG levels only in the asymptomatic group from Day 90 of the follow-up period; (iv) both prior COVID-19 disease with asymptomatic status and symptomatic status without prior COVID-19 infection resulted in similar S-IgG antibody levels; (v) significantly lower serum S-IgG levels were observed in smokers.Fever may play an important role in the post-vaccination immune response in the long term. LA - English DB - MTMT ER -